Suggested Considerations for the Treatment of Rheumatic Diseases in Adult Patients With COVID-19: Comment on the Article by Mikuls et al

Affiliations

¹ University of Virginia School of Medicine, Charlottesville, VA.
² China Medical University Hospital and China Medical University, Taichung, Taiwan.
³ Chung Shan Medical University Hospital Chung Shan Medical University and China Medical University, Taichung, Taiwan.

Comment

Jeffrey Hsu et al. Arthritis Rheumatol. 2021 Dec.

. 2021 Dec;73(12):2355.

doi: 10.1002/art.41889. Epub 2021 Oct 28.

¹ University of Virginia School of Medicine, Charlottesville, VA.
² China Medical University Hospital and China Medical University, Taichung, Taiwan.
³ Chung Shan Medical University Hospital Chung Shan Medical University and China Medical University, Taichung, Taiwan.

No abstract available

Comment on

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.
Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG. Mikuls TR, et al. Arthritis Rheumatol. 2021 Feb;73(2):e1-e12. doi: 10.1002/art.41596. Epub 2020 Dec 5. Arthritis Rheumatol. 2021. PMID: 33277981

1. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID‐19 pandemic: version 3. Arthritis Rheumatol 2021;73:e1–12. - PubMed
1. Lo CH, Wei JC, Wang YH, Tsai CF, Chan KC, Li LC, et al. Hydroxychloroquine does not increase the risk of cardiac arrhythmia in common rheumatic diseases: a nationwide population‐based cohort study. Front Immunol 2021;12:631869. - PMC - PubMed
1. Yang DH, Wang YH, Pan LF, Wei JC. Cardiovascular protection of hydroxychloroquine in patients with Sjögren's syndrome. J Clin Med 2020;9:3469. - PMC - PubMed
1. Stebbing J, Nievas GS, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARS‐CoV‐2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv 2021;7:eabe4724. - PMC - PubMed
1. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid‐19. N Engl J Med 2021;384:795–807. - PMC - PubMed